Johnson & Johnson [NYSE: JNJ] traded at a low on 02/19/21, posting a -1.67 loss after which it closed the day’ session at $162.98. The company report on February 19, 2021 that Johnson & Johnson Announces Submission to World Health Organization for Emergency Use Listing of Investigational Single-Shot Janssen COVID-19 Vaccine Candidate.
Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen-Cilag International N.V. has submitted for Emergency Use Listing (EUL) to the World Health Organization (WHO) for the investigational single-dose Janssen COVID-19 vaccine candidate. The data package delivered includes interim efficacy and safety results from the Phase 3 ENSEMBLE clinical trial. The Company’s rolling submission of clinical data to WHO is now complete.
“Our filing with the World Health Organization marks another important step in our effort to combat COVID-19 and also in our unwavering commitment to equitable access,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson. “If we are to end the global pandemic, life-saving innovations like vaccines must be within reach for all countries.”.
The results of the trading session contributed to over 8190883 shares changing hands. Over the past one week, the price volatility of Johnson & Johnson stands at 1.45% while the volatility over the past one month is 1.60%.
The market cap for JNJ stock reached $436.32 billion, with 2.63 billion shares outstanding and 2.63 billion shares in the current float. Compared to the average trading volume of 8.10M shares, JNJ reached a trading volume of 8190883 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Johnson & Johnson [JNJ]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for JNJ shares is $185.44 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on JNJ stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Johnson & Johnson shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on April 28, 2020. While these analysts kept the previous recommendation, BofA/Merrill raised their target price from $150 to $175. The new note on the price target was released on April 22, 2020, representing the official price target for Johnson & Johnson stock. Previously, the target price had yet another raise to $163, while Citigroup analysts kept a Buy rating on JNJ stock.
The Average True Range (ATR) for Johnson & Johnson is set at 2.74, with the Price to Sales ratio for JNJ stock in the period of the last 12 months amounting to 5.28. The Price to Book ratio for the last quarter was 6.65, with the Price to Cash per share for the same quarter was set at 11.50. Price to Free Cash Flow for JNJ in the course of the last twelve months was 59.93 with Quick ratio for the last quarter at 1.20.
How has JNJ stock performed recently?
Johnson & Johnson [JNJ] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.85. With this latest performance, JNJ shares gained by 0.37% in over the last four-week period, additionally plugging by 8.37% over the last 6 months – not to mention a rise of 9.85% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for JNJ stock in for the last two-week period is set at 49.54, with the RSI for the last a single of trading hit 43.29, and the three-weeks RSI is set at 52.90 for Johnson & Johnson [JNJ]. The present Moving Average for the last 50 days of trading for this stock 159.55, while it was recorded at 165.21 for the last single week of trading, and 149.83 for the last 200 days.
Johnson & Johnson [JNJ]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Johnson & Johnson [JNJ] shares currently have an operating margin of +24.11 and a Gross Margin at +71.22. Johnson & Johnson’s Net Margin is presently recorded at +17.82.
Johnson & Johnson’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.50.
Earnings analysis for Johnson & Johnson [JNJ]
With the latest financial reports released by the company, Johnson & Johnson posted 2.3/share EPS, while the average EPS was predicted by analysts to be reported at 1.99/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 15.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for JNJ. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Johnson & Johnson go to 5.31%.
Insider trade positions for Johnson & Johnson [JNJ]
There are presently around $309,869 million, or 69.80% of JNJ stock, in the hands of institutional investors. The top three institutional holders of JNJ stocks are: VANGUARD GROUP INC with ownership of 227,946,104, which is approximately -0.454% of the company’s market cap and around 0.08% of the total institutional ownership; BLACKROCK INC., holding 188,510,542 shares of the stock with an approximate value of $30.72 billion in JNJ stocks shares; and STATE STREET CORP, currently with $23.47 billion in JNJ stock with ownership of nearly -3.829% of the company’s market capitalization.
Positions in Johnson & Johnson stocks held by institutional investors increased at the end of January and at the time of the January reporting period, where 1,767 institutional holders increased their position in Johnson & Johnson [NYSE:JNJ] by around 182,005,076 shares. Additionally, 1,251 investors decreased positions by around 57,995,167 shares, while 269 investors held positions by with 1,661,271,292 shares. The mentioned changes placed institutional holdings at 1,901,271,535 shares, according to the latest SEC report filing. JNJ stock had 311 new institutional investments in for a total of 13,415,852 shares, while 60 institutional investors sold positions of 2,488,859 shares during the same period.